美国心源性休克中主动脉内球囊反搏与外周心室辅助装置的使用趋势与结局
该研究基于美国全国住院患者样本,分析2008至2017年因心源性休克非择期住院的成人患者中主动脉内球囊反搏(IABP)和经皮心室辅助装置(pVAD)的使用趋势与结局。结果显示IABP使用率下降而pVAD使用率显著上升;与IABP相比,pVAD与更高的死亡率和费用相关,但不良事件复合终点无显著差异。
要点
- 2008至2017年美国心源性休克患者中IABP使用率从23.8%降至12.7%,pVAD从0.2%升至4.5%。
- 与IABP相比,pVAD与更高的死亡风险相关(OR 1.9,95%CI 1.7-2.2)。
- pVAD与幸存者额外增加15,202美元费用、非幸存者额外增加29,643美元费用相关。
核心结论
- 研究期间pVAD用于心源性休克的比例显著增加,但与IABP相比pVAD与更高的死亡率、更高的费用及若干不良事件相关。
- 需要采用严格入选标准的多机构临床试验来评估现代背景下pVAD的临床效用。
研究设计与样本
- 回顾性分析美国全国住院患者样本(National Inpatient Sample)中2008年1月至2017年12月因心源性休克非择期住院的全部成人患者。
- 使用调查加权估计和改良Cochran-Armitage检验分析IABP与pVAD使用趋势。
- 采用多变量回归模型和逆概率治疗加权,以IABP为参照,对pVAD的死亡率、不良事件复合终点和资源使用进行风险校正分析。
主要发现
- 估计774,310例心源性休克住院患者中,143,051例接受了装置:IABP 127,792例(16.5%),pVAD 15,259例(2.0%)。
- IABP使用率从23.8%降至12.7%(趋势P<.001),pVAD植入从0.2%升至4.5%(趋势P<.001)。
- 逆概率治疗加权显示pVAD死亡比值比显著高于IABP(OR 1.9;95%CI 1.7-2.2),但不良事件复合终点无显著差异(OR 1.1;95%CI 0.96-1.27)。
- 风险校正后pVAD与幸存者额外15,202美元费用(P<.001)和非幸存者额外29,643美元费用(P<.001)相关。
临床怎么用
- 在心源性休克患者中选择机械循环支持装置时,应权衡pVAD较IABP更高的死亡风险和费用负担。
- pVAD的使用决策需结合患者具体情况,并期待严格设计的多机构临床试验提供现代证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study was to characterize practical use trends and outcomes for intraaortic balloon pump (IABP) and percutaneous left ventricular assist device (pVAD) use in cardiogenic shock at a national level. METHODS: An analysis of all adult patients admitted nonelectively for cardiogenic shock from January 2008 through December 2017 was performed using the National Inpatient Sample. Trends of inpatient IABP and pVAD use were analyzed using survey-weighted estimates and the modified Cochran-Armitage test for significance. Multivariable regression models and inverse probability of treatment weights were used to perform risk-adjusted analyses of pVAD mortality, a composite of adverse events (AE), and resource use, with IABP as reference. RESULTS: Of an estimated 774,310 patients admitted with cardiogenic shock, 143,051 received a device: IABP, 127,792 (16.5%); or pVAD, 15,259 (2.0%). IABP use decreased (23.8% to 12.7%; P for trend <.001), whereas pVAD implantation increased significantly during the study period (0.2% to 4.5%; P for trend <.001). Inverse probability of treatment weights demonstrated significantly higher odds of mortality with pVAD (odds ratio, 1.9; 95% confidence interval, 1.7 to 2.2), but not AE (odds ratio, 1.1; 95% confidence interval, 0.96 to 1.27), compared with IABP. After risk adjustment, pVAD use was associated with an additional $15,202 (P < .001) in cost for survivors and $29,643 for nonsurvivors (P < .001). CONCLUSIONS: Over the study period, the rate of pVAD use for cardiogenic shock significantly increased. Compared with IABP, pVAD use was associated with increased mortality, higher costs, and several AEs. Multi-institutional clinical trials with rigorous inclusion criteria are warranted to evaluate the clinical utility of pVADs in the modern era.
引用
- Sanaiha Y, Ziaeian B, Antonios JW, et al. Intraaortic Balloon Pump vs Peripheral Ventricular Assist Device Use in the United States. Ann Thorac Surg. 2020. PMID: 32454014. doi:10.1016/j.athoracsur.2020.03.129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。